Clinical Research Fellow – Experimental Cancer Medicine

About the role

We are looking for an ambitious, innovative individual with a strong interest in early‑phase clinical trials to join our Experimental Cancer Medicine team as a sub‑investigator. Working under consultant oversight, you will manage patients throughout their trial journey, from referral to follow‑up, and contribute to a dynamic portfolio of complex oncology studies.

Key responsibilities

• See new referrals, obtain consent, screen and enrol patients onto phase I oncology trials.
• Manage trial patients in both outpatient and inpatient settings, including follow‑up appointments.
• Participate in safety review committee meetings and liaise closely with Principal Investigators.
• Attend monthly molecular tumour board meetings to identify suitable early‑phase trial options.
• Coordinate with CROs, pharmaceutical sponsors, and external stakeholders.
• Undertake administrative duties related to patient care and trial documentation.
• Contribute to the development, planning and writing of new studies, papers and reviews.

Required profile

• Expected or completed Internal Medicine Training (IMT) by August 2026, or completed specialist training in Oncology.
• Demonstrated interest and experience in early‑phase (Phase I) clinical trials, including first‑in‑human and clinical pharmacology studies.
• Ability to work autonomously within a multidisciplinary team of consultants, research nurses and trial coordinators.
• Commitment to high‑quality patient care and adherence to NHS clinical governance standards.

Required skills

• Knowledge of Good Clinical Practice (GCP) and NHS clinical trial regulations.
• Experience with patient consent, screening and safety monitoring processes.
• Familiarity with molecular tumour board discussions and translational research workflows.

What we offer

• Salary on the NHS scale, commensurate with relevant clinical experience.
• Opportunity to work on a diverse portfolio of solid‑tumour trials, including novel small‑molecule inhibitors and combination therapies.
• Access to a supportive, highly motivated research team and regular professional development.
• Potential to present research findings at national and international conferences.